Chitomur is the Khavinson A-12 bladder peptide bioregulator. Each capsule delivers 10 mg of natural peptide complex A-12, developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson.
This is a Cytomax, meaning the peptides are filtered from animal tissue rather than built in a lab. Cytomaxes are the original form Khavinson worked with. They carry the full peptide sequence, not a shortened synthetic version of it.
Ships from a USA warehouse, ready to ship within 2 business days.
What you get
- 10 mg of natural peptide complex A-12 per capsule
- The original Khavinson formulation, not a synthetic analog
- Available as a 10-day course (20 caps) or a full 30-day course (60 caps)
- May support the normal structure and function of bladder tissue*
- Helps maintain normal protein synthesis within bladder cells*
- Supports normal bladder wall cell metabolism*
- Non-immunogenic formulation, molecular weight under 5 kDa, free from foreign DNA or protein substance
What is a bladder bioregulator?
A peptide bioregulator is a short chain of amino acids matched to one specific tissue. Short peptides are small enough to pass through the digestive tract intact, which is why these work as capsules rather than injections.
Each organ has its own peptide signature. The bladder bioregulator carries the A-12 complex, sourced from bladder tissue. Bladder wall cell metabolism is one of many things that can shift with age. The idea behind Khavinson's work is that supplying a tissue's own peptide signature gives its cells the raw signal they use to maintain normal protein synthesis.
According to PubMed, Khavinson's broader research program set out this tissue-specific peptide model and traced decades of laboratory work behind it (PMID 12374906). A 2012 paper from the same group described how short peptides bind complementary sequences in DNA, reducing the strength of proton bonds in the double helix and stimulating gene transcription, which is the proposed mechanism behind tissue-specific protein synthesis (PMID 22708439). A 2022 paper looked at how these short peptides move into cells intact, using the POT and LAT carrier systems, which is the mechanism proposed for why an oral capsule works at all (DOI 10.3390/ijms23147733). That research covers the mechanism and organ-specificity model across the whole peptide range, not a trial on A-12 by itself, and it's what the claims above are grounded in.
New to the category? Read our complete beginner's guide to peptide bioregulators or the full list of Khavinson peptide bioregulators to see how the A-number system works.
